{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:15:08Z","timestamp":1792440908407,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010687","name":"H2020 Euratom","doi-asserted-by":"publisher","award":["755523"],"award-info":[{"award-number":["755523"]}],"id":[{"id":"10.13039\/100010687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Dosimetry is rarely performed for the treatment of differentiated thyroid cancer patients with Na[<jats:sup>131<\/jats:sup>I]I (radioiodine), and information regarding absorbed doses delivered is limited. Collection of dosimetry data in a multi-centre setting requires standardised quantitative imaging and dosimetry. A multi-national, multi-centre clinical study was performed to assess absorbed doses delivered to normal organs for differentiated thyroid cancer patients treated with Na[<jats:sup>131<\/jats:sup>I]I.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients were enrolled in four centres and administered fixed activities of 1.1 or 3.7\u00a0GBq of Na[<jats:sup>131<\/jats:sup>I]I using rhTSH stimulation or under thyroid hormone withdrawal according to local protocols. Patients were imaged using SPECT(\/CT) at variable imaging time-points following standardised acquisition and reconstruction protocols. Whole-body retention data were collected. Dosimetry for normal organs was performed at two dosimetry centres and results collated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred and five patients were recruited. Median absorbed doses per unit administered activity of 0.44, 0.14, 0.05 and 0.16\u00a0mGy\/MBq were determined for the salivary glands of patients treated at centre 1, 2, 3 and 4, respectively. Median whole-body absorbed doses for 1.1 and 3.7\u00a0GBq were 0.05\u00a0Gy and 0.16\u00a0Gy, respectively. Median whole-body absorbed doses per unit administered activity of 0.04, 0.05, 0.04 and 0.04\u00a0mGy\/MBq were calculated for centre 1, 2, 3 and 4, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A wide range of normal organ doses were observed for differentiated thyroid cancer patients treated with Na[<jats:sup>131<\/jats:sup>I]I, highlighting the necessity for individualised dosimetry. The results show that data may be collated from multiple centres if minimum standards for the acquisition and dosimetry protocols can be achieved.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06295-0","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T04:01:47Z","timestamp":1686369707000},"page":"3225-3234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-2857","authenticated-orcid":false,"given":"Jan","family":"Taprogge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Vergara-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Leek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"V\u00e1vrov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Carnegie-Peake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Eberlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tino","family":"Schurrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Luster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik A.","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Vallot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Vija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Courbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Newbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Bardi\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Flux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"issue":"4","key":"6295_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"RM Tuttle","year":"2019","unstructured":"Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, consensus and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging and the European Thyroid Association. Thyroid. 2019;29(4):461\u201370.","journal-title":"Thyroid"},{"issue":"1","key":"6295_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1\u2013133.","journal-title":"Thyroid"},{"issue":"10","key":"6295_CR3","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","volume":"35","author":"M Luster","year":"2008","unstructured":"Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941\u201359.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"6295_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa2111953","volume":"386","author":"S Leboulleux","year":"2022","unstructured":"Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med. 2022;386(10):923\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"6295_CR5","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1056\/NEJMoa1109589","volume":"366","author":"U Mallick","year":"2012","unstructured":"Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674\u201385.","journal-title":"N Engl J Med"},{"issue":"1","key":"6295_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S2213-8587(18)30306-1","volume":"7","author":"HM Dehbi","year":"2019","unstructured":"Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(1):44\u201351.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"6295_CR7","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1108586","volume":"366","author":"M Schlumberger","year":"2012","unstructured":"Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663\u201373.","journal-title":"N Engl J Med"},{"issue":"2","key":"6295_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00259-009-1261-3","volume":"37","author":"GD Flux","year":"2010","unstructured":"Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(2):270\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"6295_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1089\/thy.1997.7.183","volume":"7","author":"HR Maxon","year":"1997","unstructured":"Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid. 1997;7(2):183\u20137.","journal-title":"Thyroid"},{"issue":"1","key":"6295_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/0167-8140(93)90180-G","volume":"28","author":"ME O'Connell","year":"1993","unstructured":"O\u2019Connell ME, Flower MA, Hinton PJ, Harmer CL, McCready VR. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol. 1993;28(1):16\u201326.","journal-title":"Radiother Oncol."},{"issue":"4","key":"6295_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00259-010-1689-5","volume":"38","author":"FA Verburg","year":"2011","unstructured":"Verburg FA, Lassmann M, M\u00e4der U, Luster M, Reiners C, H\u00e4nscheid H. The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients. Eur J Nucl Med Mol Imaging. 2011;38(4):673\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6295_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s42000-021-00304-3","volume":"20","author":"M Adramerinas","year":"2021","unstructured":"Adramerinas M, Andreadis D, Vahtsevanos K, Poulopoulos A, Pazaitou-Panayiotou K. Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand? Hormones (Athens). 2021;20(4):669\u201378.","journal-title":"Hormones (Athens)"},{"issue":"2","key":"6295_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.oooo.2014.10.027","volume":"120","author":"A Aliko","year":"2015","unstructured":"Aliko A, Wolff A, Dawes C, Aframian D, Proctor G, Ekstr\u00f6m J, et al. World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(2):185\u2013206.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"12","key":"6295_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1089\/thy.2007.0171","volume":"17","author":"S Subramanian","year":"2007","unstructured":"Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid. 2007;17(12):1277\u201388.","journal-title":"Thyroid"},{"issue":"5","key":"6295_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/thy.2008.0392","volume":"19","author":"AM Sawka","year":"2009","unstructured":"Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19(5):451\u20137.","journal-title":"Thyroid"},{"issue":"9","key":"6295_CR16","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1007\/s00259-022-05762-4","volume":"49","author":"MJ Reinecke","year":"2022","unstructured":"Reinecke MJ, Ahlers G, Burchert A, Eilsberger F, Flux GD, Marlowe RJ, et al. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma \u2014 a critical review and evaluation of the existing evidence. Eur J Nucl Med Mol Imaging. 2022;49(9):3247\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6295_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40658-020-00332-9","volume":"7","author":"J Taprogge","year":"2020","unstructured":"Taprogge J, Leek F, Schurrat T, Tran-Gia J, Vallot D, Bardi\u00e8s M, et al. Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project. EJNMMI Phys. 2020;7(1):61.","journal-title":"EJNMMI Phys"},{"issue":"24","key":"6295_CR18","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ab5b6c","volume":"64","author":"RA Gregory","year":"2019","unstructured":"Gregory RA, Murray I, Gear J, Leek F, Chittenden S, Fenwick A, et al. Standardised quantitative radioiodine SPECT\/CT imaging for multicentre dosimetry trials in molecular radiotherapy. Phys Med Biol. 2019;64(24): 245013.","journal-title":"Phys Med Biol"},{"key":"6295_CR19","unstructured":"MEDIRAD. http:\/\/www.medirad-project.eu\/. Last accessed 22\/03\/2023."},{"issue":"4","key":"6295_CR20","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1088\/1361-6498\/ac149a","volume":"41","author":"J Taprogge","year":"2021","unstructured":"Taprogge J, Carnegie-Peake L, Murray I, Gear JI, Flux GD. Adjustment of the iodine ICRP population pharmacokinetic model for the use in thyroid cancer patients after thyroidectomy. J Radiol Prot. 2021;41(4):1034.","journal-title":"J Radiol Prot"},{"issue":"5","key":"6295_CR21","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00259-021-05605-8","volume":"49","author":"S Schumann","year":"2022","unstructured":"Schumann S, Scherthan H, Pfestroff K, Schoof S, Pfestroff A, Hartrampf P, et al. DNA damage and repair in peripheral blood mononuclear cells after internal ex vivo irradiation of patient blood with (131)I. Eur J Nucl Med Mol Imaging. 2022;49(5):1447\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6295_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00330-016-4344-0","volume":"27","author":"D Pinto Dos Santos","year":"2017","unstructured":"Pinto Dos Santos D, Klos G, Kloeckner R, Oberle R, Dueber C, Mildenberger P. Development of an IHE MRRT-compliant open-source web-based reporting platform. Eur Radiol. 2017;27(1):424\u201330.","journal-title":"Eur Radiol"},{"key":"6295_CR23","first-page":"492","volume":"2020","author":"B Gibaud","year":"2020","unstructured":"Gibaud B, Brenet M, Pasquier G, Gil AV, Bardi\u00e8s M, Stratakis J, et al. A semantic database for integrated management of image and dosimetric data in low radiation dose research in medical imaging. AMIA Annu Symp Proc. 2020;2020:492\u2013501.","journal-title":"AMIA Annu Symp Proc"},{"issue":"4","key":"6295_CR24","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.3390\/app11041939","volume":"11","author":"A Milano","year":"2021","unstructured":"Milano A, Gil AV, Fabrizi E, Cremonesi M, Veronese I, Gallo S, et al. In Silico Validation of MCID Platform for Monte Carlo-based voxel dosimetry applied to 90Y-radioembolization of liver malignancies. Appl Sci. 2021;11(4):1939.","journal-title":"Appl Sci"},{"key":"6295_CR25","unstructured":"Pistone D. Applications of Monte Carlo simulation in internal dosimetry of radiopharmaceuticals employed in nuclear medicine [Doctoral dissertation]. Universit\u00e0 degli Studi di Messina; 2021. Available online at https:\/\/iris.unime.it\/handle\/11570\/3214160."},{"key":"6295_CR26","unstructured":"Gil AV. Implementation of a clinical dosimetry workflow to perform personalized dosimetry for internal radiotherapy [Doctoral dissertation]. Universit\u00e9 de Toulouse; 2022. Available online at https:\/\/theses.hal.science\/tel-0400827.4."},{"issue":"9","key":"6295_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, et al. 3D Slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging. 2012;30(9):1323\u201341.","journal-title":"Magn Reson Imaging"},{"key":"6295_CR28","doi-asserted-by":"crossref","unstructured":"Kikinis R, Pieper SD, Vosburgh KG. 3D Slicer: a platform for subject-specific image analysis, visualization, and clinical support. In: Jolesz FA, editor. Intraoperative imaging and image-guided therapy. New York, NY: Springer New York; 2014. p. 277\u201389.","DOI":"10.1007\/978-1-4614-7657-3_19"},{"issue":"10","key":"6295_CR29","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.2967\/jnumed.119.240366","volume":"61","author":"M Chauvin","year":"2020","unstructured":"Chauvin M, Borys D, Botta F, Bzowski P, Dabin J, Denis-Bacelar AM, et al. OpenDose: open-access resource for nuclear medicine dosimetry. J Nucl Med. 2020;61(10):1514\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"6295_CR30","first-page":"648","volume":"47","author":"H H\u00e4nscheid","year":"2006","unstructured":"H\u00e4nscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47(4):648\u201354.","journal-title":"J Nucl Med"},{"issue":"6","key":"6295_CR31","doi-asserted-by":"publisher","DOI":"10.1118\/1.4871617","volume":"41","author":"D Sarrut","year":"2014","unstructured":"Sarrut D, Bardi\u00e8s M, Boussion N, Freud N, Jan S, L\u00e9tang JM, et al. A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications. Med Phys. 2014;41(6): 064301.","journal-title":"Med Phys"},{"issue":"10","key":"6295_CR32","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1118\/1.3602459","volume":"38","author":"B Liu","year":"2011","unstructured":"Liu B, Huang R, Kuang A, Zhao Z, Zeng Y, Wang J, et al. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer. Med Phys. 2011;38(10):5412\u20139.","journal-title":"Med Phys"},{"issue":"6","key":"6295_CR33","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Lind\u00e9n O, Flux G. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6295_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J Nucl Med. 2009;50(3):477\u201384.","journal-title":"J Nucl Med."},{"issue":"9","key":"6295_CR35","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2967\/jnumed.109.064469","volume":"50","author":"SE Buckley","year":"2009","unstructured":"Buckley SE, Chittenden SJ, Saran FH, Meller ST, Flux GD. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009;50(9):1518\u201324.","journal-title":"J Nucl Med"},{"issue":"5","key":"6295_CR36","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s00259-009-1351-2","volume":"37","author":"W Jentzen","year":"2010","unstructured":"Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic 124I PET(\/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(5):884\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2 Suppl","key":"6295_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0146645314558019","volume":"44","author":"S Mattsson","year":"2015","unstructured":"Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, No\u00dfke D, Riklund K, et al. Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances. Ann ICRP. 2015;44(2 Suppl):7\u2013321.","journal-title":"Ann ICRP"},{"issue":"1","key":"6295_CR38","first-page":"143","volume":"48","author":"KS Kolbert","year":"2007","unstructured":"Kolbert KS, Pentlow KS, Pearson JR, Sheikh A, Finn RD, Humm JL, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med. 2007;48(1):143\u20139.","journal-title":"J Nucl Med"},{"issue":"12","key":"6295_CR39","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1089\/thy.2015.0173","volume":"25","author":"GB Coura-Filho","year":"2015","unstructured":"Coura-Filho GB, Willegaignon J, Buchpiguel CA, Sapienza MT. Effects of thyroid hormone withdrawal and recombinant human thyrotropin on glomerular filtration rate during radioiodine therapy for well-differentiated thyroid cancer. Thyroid. 2015;25(12):1291\u20136.","journal-title":"Thyroid"},{"issue":"3","key":"6295_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.23736\/S1824-4785.19.03202-3","volume":"63","author":"J Taprogge","year":"2019","unstructured":"Taprogge J, Leek F, Flux GD. Physics aspects of setting up a multicenter clinical trial involving internal dosimetry of radioiodine treatment of differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2019;63(3):271\u20137.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"2","key":"6295_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.clon.2020.12.002","volume":"33","author":"J Taprogge","year":"2021","unstructured":"Taprogge J, Wadsley J, Miles E, Flux GD. Recommendations for multicentre clinical trials involving dosimetry for molecular radiotherapy. Clin Oncol. 2021;33(2):131\u20136.","journal-title":"Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06295-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:02:59Z","timestamp":1695970979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06295-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6295"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06295-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,10]]},"assertion":[{"value":"23 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional and\/or national research committees (see Supplementary Table\u00a0) and with the 1964 Helsinki Declaration and later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors read the manuscript and approved its publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FAV has received speaker honoraria from Sanofi and AstraZeneca (all honoraria paid to employer) as well as consultancy honoraria from GE Healthcare (all honoraria paid to employer). LV has received honoraria from EISAI and AAA. FC has received honoraria from MAB, Novartis and AAA.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}